Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Aligos Therapeutics, Inc. reported significant progress in its clinical studies and financial results for Q4 and full year 2025, focusing on therapies for liver and viral diseases [1][2]. Recent Business Progress - The company is advancing its global Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection, with enrollment in both HBeAg- and HBeAg+ cohorts ongoing [2][5]. - Aligos has partnered with Xiamen Amoytop Biotech Co., Ltd. to advance ALG-170675, a dual mechanism antisense oligonucleotide (ASO), into IND-enabling studies [2][5]. - The appointment of James Hassard as Executive Vice President, Chief Commercial Officer, aims to enhance the company's global commercial capabilities [7]. Pipeline Updates - Pevifoscorvir sodium is positioned as a potential first-/best-in-class small molecule for chronic HBV infection [3]. - ALG-170675 is being developed as a potential best-in-class ASO for chronic HBV infection [4]. - ALG-055009 shows promise as a small molecule for obesity and metabolic dysfunction-associated steatohepatitis (MASH), with recent studies indicating significant weight loss benefits when combined with other therapies [4][6]. Financial Results - As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $77.8 million, an increase from $56.9 million in 2024, expected to fund operations into Q3 2026 [8]. - The net loss for Q4 2025 was $19.9 million, a significant reduction from a net loss of $82.2 million in Q4 2024 [9]. - For the full year 2025, the net loss was $24.2 million, down from $131.2 million in 2024 [10]. - Research and development expenses for Q4 2025 were $17.0 million, slightly up from $16.0 million in Q4 2024, primarily due to increased costs associated with the pevifoscorvir sodium Phase 2 trial [11]. - General and administrative expenses for Q4 2025 were $4.9 million, down from $5.2 million in Q4 2024, attributed to reduced legal and related expenses [13].